Original Article

Cytoreductive Surgery and Hyperthermic İntraperitoneal Chemoterapy for Advance Gastric Cancer Associated Peritoneal Carcinomatosis Single Centre Unit for 10 Consecutive Patients


  • Özgül Düzgün
  • Sema Yüksekdağ
  • Murat Kalın
  • Şenol Çomoğlu
  • Semra Yanık
  • Ömer Faruk Özkan
  • Neşet Köksal

Received Date: 07.02.2019 Accepted Date: 07.03.2019 Med Bull Haseki 2019;57(3):267-273


Hyperthermic intraperitoneal chemotherapy with cytoreductive surgery has a positive effect on survival in advanced abdominal cancers. We aimed to present our experience with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in gastric cancer patients with peritoneal carcinomatosis and a review of the literature.


Ten patients (seven male, three female) who were diagnosed with gastric cancer between June 2017 and November 2018 were included in the study. Data on demographic characteristics, short-term follow-up results, surgical findings, peritoneal carcinomatosis index score, completeness of cytoreduction score, and morbidity and mortality rates were retrospectively analyzed.


The mean age of the patients was 60.3 years. The mean follow-up period was six months (1-15 months). One patient developed an anastomotic leak. In the other nine cases, there was no morbidity leading to mortality.


While gastric cancer with peritoneal carcinomatos has a poor survival, less than six months with non-operative approach, treatment with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy offers better outcomes and overall survival. Our first results in our study with a limited number of patients are satisfactory and multicentric randomized studies are needed on this subject.

Keywords: Gastric cancer, peritoneal carcinomatosis, cytoreductive surgery, hyperthermic intraperitoneal chemotherapy

Full Text (Turkish)